Edwards Lifesciences Corporation: 10-K Risk Factor Changes

2026 vs 2025  ·  SEC EDGAR  ·  2026-05-22
Other years: 2025 vs 2024 · 2024 vs 2023
⚠ AI-Generated

The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.

Edwards Lifesciences added five new risk factors in 2026, including prominent disclosures on AI implementation, global economic and political conditions, and international operations, while substantively modifying six existing risks related to physician dependencies and healthcare regulation compliance. The company eliminated no previously disclosed risks, indicating a net expansion of risk factor coverage that reflects emerging business challenges without retiring legacy concerns. This expansion suggests Edwards is addressing material shifts in its operating environment, particularly around technology adoption and geopolitical exposure.

✓ Deterministic extraction — no AI-generated data

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

5
New Risks
0
Removed
6
Modified
18
Unchanged
🟢 New in Current Filing

Our use of, or our failure to effectively and timely utilize, emerging technologies, including AI, could adversely impact our business and financial results.

We use AI and other emerging technologies in various facets of our operations and our business. The legal and regulatory landscape surrounding AI technologies is rapidly evolving and uncertain. The rapid advancement of these technologies entails risks, including potential…

Read full text

We use AI and other emerging technologies in various facets of our operations and our business. The legal and regulatory landscape surrounding AI technologies is rapidly evolving and uncertain. The rapid advancement of these technologies entails risks, including potential deficiencies in AI-generated information and increased regulatory, cybersecurity, privacy, intellectual property and data-related risks. Another risk may arise if we are unable to timely utilize AI for technological innovation and business operation efficiency in a manner that is faster and more effective than our competitors. In addition, compliance with new or changing laws, regulations or industry standards relating to AI may impose significant costs on us and limit our ability to effectively develop, deploy or use AI technologies. Furthermore, if we are unable to effectively manage the use of AI technologies by our employees and service providers, our confidential information, intellectual property and reputation could be put at risk. Failure to appropriately respond to this evolving landscape may result in reputational, competitive and business harm as well as litigation and regulatory action and fines, penalties and expenses related thereto.

🟢 New in Current Filing We may be adversely impacted by global economic, political and social conditions. 🔒
🟢 New in Current Filing Our international operations subject us to certain business risks. 🔒
🟢 New in Current Filing Health care legislation and other regulations may adversely impact access to and demand for our products. 🔒
🟢 New in Current Filing We are subject to litigation, investigations, and other legal proceedings relating to our products, customers, competitors, and government regulators that could materially adversely affect our financial condition, divert management’s attention, and harm our business. 🔒
🟡 Modified The success of many of our products depends upon certain key physicians, research institutions, and hospital systems. 🔒
🟡 Modified Summary of Risk Factors 🔒
🟡 Modified We and our customers are subject to healthcare legislation and other rigorous governmental regulations and we may incur significant expenses to comply with these regulations. In addition, failure to comply with these regulations could subject us to substantial sanctions and may impact our ability to sell our products in certain countries which could adversely affect our business, financial condition, and results of operations. 🔒
🟡 Modified We operate in highly competitive markets, and if we do not compete effectively, our business will be harmed. 🔒
🟡 Modified We face a number of risks related to our income taxes in the United States as well as other jurisdictions. 🔒
🟡 Modified We are subject to risks associated with public health crises. 🔒
10 more changes in this filing

Full diff access, historical comparisons, and cross-company signal tracking.

Get full access — from $29/month Already a Pro subscriber? View full diff →